Predictors of self-perceived health worsening over COVID-19 emergency in ALS.


Journal

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 30 09 2020
accepted: 12 12 2020
pubmed: 15 1 2021
medline: 26 3 2021
entrez: 14 1 2021
Statut: ppublish

Résumé

Factors influencing self-perceived health status over Corona Virus Disease 2019 (COVID-19) emergency in vulnerable populations, such as patients with chronic neurological diseases, are still unknown. In this work, we aimed at testing whether clinical care changes imposed by the quarantine, together with certain demographic and disease-specific features, might have determined a self-perceived worsening of health status in patients with amyotrophic lateral sclerosis (ALS). A brief web-based questionnaire investigating self-perceived anxiety, depression, and motor worsening, as well as clinical care changes over COVID-19 emergency, was administered to ALS patients currently followed at San Martino Hospital. Ordinal and logistic regression analyses were applied to identify significant predictors of health status. Fifty-seven ALS patients completed the questionnaire. A total of 35.08% of cases reported anxiety symptoms, 36.84% depressive symptoms, and 35.08% reported worsening of motor symptoms. Significant predictors of anxiety symptoms severity included female gender, greater motor impairment, more aggressive disease course, and rehabilitation therapy suspension. The only significant predictor of depressive symptoms severity was a more aggressive disease course. Significant predictors of motor worsening were shorter disease duration and exams/visits cancelation. COVID-19 emergency and its management exerted a significant impact on self-perceived health status in patients with ALS, particularly in those cases in the earliest disease phases and with a more aggressive disease course. These findings have potential to improve personalized medicine strategies in the next phase.

Identifiants

pubmed: 33443667
doi: 10.1007/s10072-020-04997-z
pii: 10.1007/s10072-020-04997-z
pmc: PMC7807220
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1231-1236

Références

Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323:1775–1776
Manji H, Carr AS, Browlee WJ, Lunn MP (2020) Neurology in the time of covid-19. J Neurol Neurosurg Psychiatry 91:568–570
doi: 10.1136/jnnp-2020-323414
Brooks BR, Miller RG, Swash M, Munsat TL (2000) World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299
doi: 10.1080/146608200300079536
Chiò A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82(7):740–746
doi: 10.1136/jnnp.2010.235952
Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, Willey E, Ampong MA, Ellis CM, Shaw CE, al-Chalabi A, Leigh PN (2009) Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 72(12):1087–1094
doi: 10.1212/01.wnl.0000345041.83406.a2
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169(1-2):13–21
doi: 10.1016/S0022-510X(99)00210-5
De Lucia N, Ausiello FP, Spisto M, Manganelli F, Salvatore E, Dubbioso R (2020) The emotional impact of COVID-19 outbreak in amyotrophic lateral sclerosis patients: evaluation of depression, anxiety and interoceptive awareness. Neurol Sci 41(9):2339–2341
doi: 10.1007/s10072-020-04592-2
Cui F, Zhu W, Zhou Z, Ren Y, Li Y, Li M, Huo Y, Huang X (2015) Frequency and risk factor analysis of cognitive and anxiety-depressive disorders in patients with amyotrophic lateral sclerosis/motor neuron disease. Neuropsychiatr Dis Treat 11:2847–2854
pubmed: 26604769 pmcid: 4639547
Özdin S, Bayrak Özdin Ş (2020) Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: the importance of gender. Int J Soc Psychiat 66(5):504–511
doi: 10.1177/0020764020927051
Jakobsson Larsson B, Ozanne AG, Nordin K, Nygren I (2017) A prospective study of quality of life in amyotrophic lateral sclerosis patients. Acta Neurol Scand 136(6):631–638
doi: 10.1111/ane.12774
Prell T, Steinbach R, Witte OW, Grosskreutz J (2019) Poor emotional well-being is associated with rapid progression in amyotrophic lateral sclerosis. eNeurologicalSci 16:100
doi: 10.1016/j.ensci.2019.100198
Hillemacher T, Grässel E, Tigges S, Bleich S, Neundörfer B, Kornhuber J et al (2004) Depression and bulbar involvement in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 5(4):245–249
doi: 10.1080/14660820410021294
Edge R, Mills R, Tennant A, Diggle PJ, Young CA, TONiC study group (2020) Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature. J Neurol 267(3):607–615
doi: 10.1007/s00415-019-09615-3
Andrews JA, Berry JD, Baloh RH, Carberry N, Cudkowicz ME, Dedi B et al (2020) Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: challenges and opportunities. Muscle Nerve 62(2):1
doi: 10.1002/mus.26989
Consonni M, Telesca A, Dalla Bella E, Bersano E, Lauria G (2020) Amyotrophic lateral sclerosis patients' and caregivers' distress and loneliness during COVID-19 lockdown. J Neurol 21:1–4
De Marchi F, Cantello R, Ambrosini S, Mazzini L, CANPALS Study Group (2020) Telemedicine and technological devices for amyotrophic lateral sclerosis in the era of COVID-19. Neurol Sci 41(6):1365–1367
doi: 10.1007/s10072-020-04457-8
Bombaci A, Abbadessa G, Trojsi F, Leocani L, Bonavita S, Lavorgna L, Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology (2020) Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail. Neurol Sci 6:1–5
Vasta R, Moglia C, D'Ovidio F, Di Pede F, De Mattei F, Cabras S et al (2020) Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. Amyotroph Lateral Scler Frontotemporal Degener 12:1–4
Capozzo R, Zoccolella S, Musio M, Barone R, Accogli M, Logroscino G (2020) Telemedicine is a useful tool to deliver care to patients with amyotrophic lateral sclerosis during COVID-19 pandemic: results from southern Italy. Amyotroph Lateral Scler Frontotemporal Degener 21(7–8):542–548
doi: 10.1080/21678421.2020.1773502

Auteurs

Corrado Cabona (C)

Division of Clinical Neurophysiology and Epilepsy Center, Ospedale Policlinico San Martino, IRCCS, Largo R. Benzi 10, 16132, Genoa, Italy. corrado.cabona@gmail.com.

Pilar M Ferraro (PM)

Department of Neuroradiology, Ospedale Policlinico San Martino, IRCCS, Genoa, Italy.

Giuseppe Meo (G)

Department of Neurology, Ospedale Policlinico San Martino, IRCCS, Genoa, Italy.

Luca Roccatagliata (L)

Department of Neuroradiology, Ospedale Policlinico San Martino, IRCCS, Genoa, Italy.

Angelo Schenone (A)

Department of Neurology, Ospedale Policlinico San Martino, IRCCS, Genoa, Italy.

Matilde Inglese (M)

Department of Neurology, Ospedale Policlinico San Martino, IRCCS, Genoa, Italy.

Flavio Villani (F)

Division of Clinical Neurophysiology and Epilepsy Center, Ospedale Policlinico San Martino, IRCCS, Largo R. Benzi 10, 16132, Genoa, Italy.

Claudia Caponnetto (C)

Department of Neurology, Ospedale Policlinico San Martino, IRCCS, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH